Free Access to TSR Screeners - Sign Up for Your Nightly Pass
Birds's Eye
Technicals
MovingAverage
Candlestick
PivotPoint
Fin Statements
Beta&Vols
Tech ChartsFundamental Analysis of Balaxi Pharmaceuticals Ltd. - Growth / Value Index
BALAXI - Valuation Highlights
Valuation Analysis
Tsr Value Index - Good Score of 66.67
Undervalued - Price to Intrinsic Value of 0.274
Price to Earning Ratio is 12.59 and EV to EBITDA is 9.02 suggesting company is undervalued.
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ | Screener/ About |
|---|---|---|---|---|---|
| Price to Earning | 12.63 | 14.08 | 132.93 % | ||
| Price to Book | 1.05 | 1.52 | 200.14 % | 0.512 | |
| Price to Sales | 0.801 | 1.21 | 184.89 % | ||
| Enterprise Value to EBITDA Multiple | 10.90 | 6.67 % |
BALAXI - Profitability Highlights
Profitability Analysis
Earning Yield of 7.94 %
Net profit has jumped from negative to positive
Piotroski F Score - Stable Value of 4.0
Tsr Profitability Index - Poor Score of 25.78
Very Low Dividend Yield of 0 %
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ | Screener/ About |
|---|---|---|---|---|---|
| Return On Equity | 8.61 | 10.82 | 1011.44 % | 0.125 | |
| Return On Asset | 6.49 | 8.08 | 973.19 % | 0.093 | |
| Net Profit Margin | 6.34 | 8.57 | 965.13 % | 0.410 | |
| Operating Profit Margin | 55.55 | 11.07 | -37.82 % | 5.87 | |
| EBITDA Margin | 9.29 | 11.45 | 376.22 % | 3.35 |
Highlights
| Market Cap | 2378.34 M |
| Enterprise Value | 2500.54 M |
| Price/Book TTM | 1.05 |
| Outstanding Share | 55207.50 K |
| Float/ Outstanding Share | 92.73% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | 0.759 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 4.00 |
| Altman Z Score | 4.82 |
| Sloan Ratio | 0.264 |
| Peter Lynch Fair Value | 85.29 |
BALAXI - Growth Highlights
Growth Analysis
Steady increase in Total Assets for last 3 Years
Operating Cash Flow decreasing for last 3 year
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 297.68 (Cr) | 21.25 % | 7.25 % |
| Gross Profit | 122.64 (Cr) | 11.42 % | 7.80 % |
| EBITDA | 27.64 (Cr) | 477.41 % | 78.20 % |
| Net Profit | 18.88 (Cr) | 1148.95 % | 96.64 % |
| EPS | 3.41 | 295.69 % | NA |
BALAXI - Stability Highlights
Stability Analysis
Tsr Stability Index - Excellent Score of 92.50
Altman Z Score of 4.81 suggests good Stability
Company financial liquidity has improved
Company is unable to generate enough free cash to support the business.
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ | Screener/ About |
|---|---|---|---|---|
| Debt to Equity Ratio | 0.223 | 131.19 % | 0.223 | |
| Cash Ratio | 0.723 | -37.13 % | ||
| Quick Ratio | 3.01 | 27.57 % | 3.01 | |
| Shareholders Equity | 74.67 | -4.20 % | ||
| Debt to EBITDA | 1.54 | -53.92 % |
Historical Valuation Ratios of Balaxi Pharmaceuticals Ltd.
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Balaxi Pharmaceuticals Ltd.
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Balaxi Pharmaceuticals Ltd.
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Balaxi Pharmaceuticals Ltd.
Historical Solvency Ratios
Loading ...